-
公开(公告)号:US08207110B2
公开(公告)日:2012-06-26
申请号:US11661877
申请日:2005-09-01
IPC分类号: A61K38/00
CPC分类号: C07K14/70503 , C07K2319/30
摘要: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译: 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽,其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地附着于(ii)免疫球蛋白的Fc部分,其中所述免疫球蛋白的Fc部分包含功能增强突变,并且其中 该多肽是水溶性的。 本发明还提供了第三多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地固定于(ii)跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸,表达载体,宿主载体系统,组合物和制品以及治疗和预防方法。
-
公开(公告)号:US20090202544A1
公开(公告)日:2009-08-13
申请号:US12223496
申请日:2007-02-02
IPC分类号: A61K39/395 , A61K35/14 , C12Q1/68 , A61K31/7088 , C07H21/04
CPC分类号: C07K16/2803 , A61K35/14 , C07K14/70503 , C07K2319/30 , G01N33/57488
摘要: This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also provides the above method, further comprising administering an anti-ILT3 antibody to the subject. The invention also provides a method of treating a subject afflicted with a disease, comprising administering to the subject an anti-ILT3 antibody, thereby treating the subject. In one embodiment, the disease is chronic viral disease. In another embodiment, the disease is cancer.
摘要翻译: 本发明提供一种治疗患有疾病的受试者的方法,包括从受试者中取出血液,处理所抽取的血液,以从血液中除去sILT3,并将经处理的血液返回给受试者,由此治疗患有 疾病。 本发明还提供了上述方法,其还包括对受试者施用抗ILT3抗体。 本发明还提供了治疗患有疾病的受试者的方法,其包括向受试者施用抗ILT3抗体,从而治疗受试者。 在一个实施方案中,该疾病是慢性病毒性疾病。 在另一个实施方案中,该疾病是癌症。
-
公开(公告)号:US20120321623A1
公开(公告)日:2012-12-20
申请号:US13480421
申请日:2012-05-24
IPC分类号: A61K38/17 , C07K19/00 , C12N5/0783 , A61P37/06 , A61K39/395
CPC分类号: C07K14/70503 , C07K2319/30
摘要: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译: 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽,其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地附着于(ii)免疫球蛋白的Fc部分,其中所述免疫球蛋白的Fc部分包含功能增强突变,并且其中 该多肽是水溶性的。 本发明还提供了第三多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地固定于(ii)跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸,表达载体,宿主载体系统,组合物和制品以及治疗和预防方法。
-
公开(公告)号:US20090274685A1
公开(公告)日:2009-11-05
申请号:US12419824
申请日:2009-04-07
IPC分类号: A61K39/395
CPC分类号: C07K14/70503 , A61K38/1774 , A61K39/001 , A61K45/06 , C07K2319/30
摘要: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
摘要翻译: 本发明提供了一种抑制移植胰岛细胞排斥反应的方法,包括向受试者施用包含全部或部分ILT3细胞外结构域的多肽,其中多肽是水溶性的。 本发明进一步提供了一种治疗糖尿病的方法,其通过向受试者施用多肽来抑制移植的胰岛细胞的排斥。
-
公开(公告)号:US20080311073A1
公开(公告)日:2008-12-18
申请号:US11661877
申请日:2005-09-01
IPC分类号: A61K45/00 , C07K14/00 , C12N15/11 , C12N15/00 , A61P37/00 , A61K35/12 , C12N5/06 , C12P21/04
CPC分类号: C07K14/70503 , C07K2319/30
摘要: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译: 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽,其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地附着于(ii)免疫球蛋白的Fc部分,其中所述免疫球蛋白的Fc部分包含功能增强突变,并且其中 该多肽是水溶性的。 本发明还提供了第三多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地固定于(ii)跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸,表达载体,宿主载体系统,组合物和制品以及治疗和预防方法。
-
公开(公告)号:US06759239B2
公开(公告)日:2004-07-06
申请号:US09746311
申请日:2000-12-21
IPC分类号: C12N500
CPC分类号: G01N33/56972 , A61K35/12 , A61K39/001 , A61K2035/124 , A61K2039/5156 , C12N2510/00
摘要: This invention provides a method of generating antigen specific allospecific human suppressor CD8+CD28− T cells. This invention also provides a method of generating xenospecific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of treatment for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provides, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
摘要翻译: 本发明提供了产生抗原特异性异体人抑制因子CD8 + CD28-T细胞的方法。 本发明还提供了产生异种人抑制CD8 + CD28-T细胞的方法。 本发明还提供了产生抗原特异性抗体抑制剂CD8 + CD28-T细胞的方法。 使用如此产生的人抑制剂CD8 + CD28-T细胞降低同种异体移植物和异种移植物和自身免疫疾病排斥风险的治疗方法也提供了预防排斥反应和自身免疫性疾病的方法以及包含所产生的抑制性T细胞的疫苗 。 提供诊断方法以确定免疫抑制剂治疗水平是否需要减少。
-
公开(公告)号:US20160152682A1
公开(公告)日:2016-06-02
申请号:US14733432
申请日:2015-06-08
IPC分类号: C07K14/705 , A61K38/17 , A61K45/06
CPC分类号: C07K14/70503 , A61K38/1774 , A61K39/001 , A61K45/06 , C07K2319/30
摘要: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
-
公开(公告)号:US09150635B2
公开(公告)日:2015-10-06
申请号:US13480421
申请日:2012-05-24
IPC分类号: A61K38/16 , C07K14/705
CPC分类号: C07K14/70503 , C07K2319/30
摘要: This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译: 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽,其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地附着于(ii)免疫球蛋白的Fc部分,其中所述免疫球蛋白的Fc部分包含功能增强突变,并且其中 该多肽是水溶性的。 本发明还提供了第三多肽,其包含(i)ILT3的全部或部分细胞外结构域可操作地固定于(ii)跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸,表达载体,宿主载体系统,组合物和制品以及治疗和预防方法。
-
公开(公告)号:US09078858B2
公开(公告)日:2015-07-14
申请号:US13621961
申请日:2012-09-18
CPC分类号: C07K14/70503 , A61K38/1774 , A61K39/001 , A61K45/06 , C07K2319/30
摘要: This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
摘要翻译: 本发明提供了一种抑制移植胰岛细胞排斥反应的方法,包括向受试者施用包含全部或部分ILT3细胞外结构域的多肽,其中多肽是水溶性的。 本发明进一步提供了一种治疗糖尿病的方法,其通过向受试者施用多肽来抑制移植的胰岛细胞的排斥。
-
公开(公告)号:US07144728B1
公开(公告)日:2006-12-05
申请号:US10018677
申请日:2000-06-15
CPC分类号: G01N33/56972 , A61K35/12 , A61K39/001 , A61K2035/124 , A61K2039/5156 , C12N2510/00
摘要: This invention also provides a method of generating antigen specific human suppressor CD8+CD28− T cells. This invention further provides a method of generating allopeptide antigen specific human suppressor CD8+CD28− T cells. Methods of tent for reduction of risk of rejection of allografts and xenografts and autoimmune diseases using the human suppressor CD8+CD28− T cells so produced are also provided, as are methods of preventing rejection and autoimmune diseases, and vaccines comprising the produced suppressor T cells. Methods of diagnosis to determine whether a level of immuno-suppressant therapy requires a reduction are provided.
摘要翻译: 本发明还提供了产生抗原特异性人抑制剂CD8 + CD28-T细胞的方法。 本发明还提供了产生抗原特异性抗体抑制剂CD8 + CD28-T细胞的方法。 还提供了使用如此产生的人抑制剂CD8 + CD28-T细胞降低同种异体移植物和异种移植物和自身免疫疾病排斥风险的帐篷的方法,以及预防排斥反应和自身免疫性疾病的方法以及包含所产生的抑制性T细胞的疫苗 。 提供诊断方法以确定免疫抑制剂治疗水平是否需要减少。
-
-
-
-
-
-
-
-
-